- Home
- PTA vs XNCR Comparison
PTA vs XNCR Comparison
Compare PTA & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTA | XNCR |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 881.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PTA | XNCR |
|---|---|---|
| Price | $19.29 | $12.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 126.5K | ★ 682.7K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $18.13 | $6.92 |
| 52 Week High | $20.92 | $18.69 |
Technical Indicators
Market Signals| Indicator | PTA | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 46.52 |
| Support Level | $19.02 | $10.93 |
| Resistance Level | $19.74 | $12.87 |
| Average True Range (ATR) | 0.22 | 0.69 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 44.54 | 8.97 |
Price Performance
Historical ComparisonAbout PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.